Systemic bevacizumab for retinal angiomatous proliferation associated with retinal pigment epithelial detachment.
Journal - European journal of ophthalmology (Italy )
PURPOSE: To report the off-label use of systemic bevacizumab in a patient with stage 3 retinal angiomatous proliferation (RAP) associated with a vascularized pigmented epithelium detachment (PED). METHODS: Interventional case report. RESULTS: The patient was treated with systemic bevacizumab after obtaining fully informed consent. At 3 months post-treatment, the authors observed an improvement of one line (seven letters) in visual acuity and total regression of the PED on ocular coherence tomography. No adverse effects were observed. CONCLUSIONS: Systemic bevacizumab therapy appears to be safe and effective in the treatment of RAP associated with PED during this short follow-up period of 3 months. The authors recommend a large trial with long-term follow-up to confirm the promising results and evaluate the occurrence of adverse effects associated with systemic bevacizumab.
|ISSN : ||1120-6721|
|Mesh Heading : ||Aged Angiogenesis Inhibitors Angiomatosis Antibodies, Monoclonal Female Fluorescein Angiography Humans Injections, Intravenous Macular Degeneration Pigment Epithelium of Eye Retinal Detachment Retinal Neovascularization Tomography, Optical Coherence Vascular Endothelial Growth Factor A Visual Acuity diagnosis diagnosis diagnosis diagnosis|
|Mesh Heading Relevant : ||therapeutic use drug therapy therapeutic use drug therapy pathology drug therapy drug therapy|